Twist Bioscience (TWST) Q1 2026 earnings review
Strong Beat and Guidance Raise, But Profitability Takes a Deliberate Step Back
Twist delivered its 12th consecutive quarter of growth with record revenue of $103.7M, beating guidance of $100-101M by 3%. DNA Synthesis & Protein Solutions surged 27% YoY, powered by AI-enabled drug discovery demand. The company raised full-year revenue guidance to $435-440M from $425-435M—more than double the Q1 beat at the midpoint. Gross margin held at 52.0%, up ~4 points YoY. However, SG&A expenses jumped 24% YoY as management front-loaded investments in sales headcount and digital infrastructure, pushing Adjusted EBITDA loss to -$13.4M—worse sequentially from -$7.8M in Q4 FY25. Management insists Q4 FY26 EBITDA breakeven remains on track.
🐂 Bull Case
DSPS revenue surged 27% YoY, driven by repeat orders from large pharma, big tech, and well-funded biotechs building AI models. Orders from AI customers exceeded $25M in FY25 and are accelerating. Customers are returning for larger, recurring workflows—not one-time experiments.
Management raised FY26 guidance by ~$7.5M at midpoint—more than double the Q1 beat. The raise was balanced across both DSPS and NGS, suggesting confidence isn't limited to a single segment or customer.
52.0% gross margin in Q1 confirms the structural improvement from 42.6% in FY24. The company continues to convert ~74-80% of incremental revenue to gross profit, validating the operating leverage of the silicon-based platform.
🐻 Bear Case
Adj. EBITDA loss nearly doubled sequentially from -$7.8M (Q4 FY25) to -$13.4M, driven by a ~$10M/quarter OpEx increase. Management is betting this investment accelerates growth, but the lag between spending and returns introduces execution risk for the Q4 breakeven target.
NGS Applications grew just 8% YoY—the slowest rate in at least two years. Even excluding the transitioning customer, growth was 18%, a deceleration from 27% in Q3 FY25 and 23% for full-year FY25. Diagnostics revenue was flat YoY at $35.3M.
Cash and investments fell to $198M from $232M at FY25-end, a $34.5M decline in one quarter. At this burn rate, the company has roughly 5-6 quarters of runway—adequate only if the EBITDA breakeven timeline holds.
⚖️ Verdict: 🟢
Moderately Bullish. The DSPS acceleration and guidance raise are genuinely encouraging, and the gross margin trajectory validates the platform's leverage. The deliberate OpEx ramp is the right strategy if AI demand is as durable as management claims, but it introduces near-term EBITDA risk. NGS weakness is manageable if the transitioning customer returns as expected in Q2. The key test: does the Q4 EBITDA breakeven hold?
Key Themes
AI-Enabled Discovery Emerging as a Structural Growth Engine
The AI-discovery thesis that began forming in early 2025 is now generating visible, accelerating revenue. DSPS grew 27% YoY to $51.1M—up from ~18% growth in Q4 FY25. Three customer types are driving demand: large pharma building language models, big tech 'dry labs' relying entirely on Twist for wet lab work, and well-funded biotechs. The workflow has evolved from exploratory orders to repeat production-level engagements. Customers design thousands of sequences, Twist synthesizes DNA, expresses proteins, and delivers characterization data—charging $200-400 per antibody characterization versus $50-100 for basic DNA. Management sees an immediately addressable market of $1.5B (antibody discovery) plus $700M (protein expression). Over 50,000 genes were manufactured for data characterization in Q1 alone, on top of 271,000 genes shipped—a metric disclosed for the first time because internal characterization volumes have become material.
NGS Growth Deceleration Deepens
NGS Applications revenue grew just 8% YoY to $52.6M—a sharp deceleration from 27% in Q3 FY25 and 23% for the full year. Even adjusting for the large customer transitioning from research to commercial, growth was 18%, still below prior run rates. Diagnostics revenue was essentially flat at $35.3M vs $35.5M. The single-customer headwind has persisted for two quarters now (first flagged in Q3 FY25 as a '$5M normalization'). Management projects re-acceleration in Q2 with strong sequential growth, stating the customer's orders are now 'in.' The top 10 NGS customers' share dropped to 36% of NGS revenue from 44% in Q3 FY25, suggesting concentration risk is easing but existing large accounts may be plateauing.
SG&A Spending Surge Raises the Execution Bar
SG&A jumped 24% YoY to $69.7M from $56.2M—adding $13.5M in a single quarter. This wasn't a gradual ramp: Q4 FY25 SG&A was $63.8M, so the sequential increase was $5.9M. Management attributes this to structural investments (hiring salespeople while competitors are laying off) and transient investments (contractors for digital infrastructure, including the first e-commerce platform for NGS Applications). CEO Leproust described it as a deliberate ~$10M/quarter increase, framing it as a 'turbo on an engine' with a lag before acceleration shows in revenue. The risk: if the growth payoff takes longer than expected, the Q4 FY26 EBITDA breakeven target becomes very tight.
Adjusted EBITDA Reversal Breaks the Improvement Trend
Adjusted EBITDA loss widened to -$13.4M from -$7.8M in Q4 FY25, breaking four consecutive quarters of sequential improvement: -$16.3M → -$14.8M → -$8.0M → -$7.8M → -$13.4M. The $5.6M sequential deterioration was entirely driven by the OpEx ramp, since gross profit actually increased ($54.0M vs $50.8M in Q4). Management expects these investments to 'remain stable or moderate slightly' in H2, meaning Q2 EBITDA could be similar before improving in Q3-Q4. Reaching breakeven in Q4 now requires roughly $13-14M of sequential EBITDA improvement over three quarters—possible but aggressive.
Therapeutics Vertical Accelerating Fastest
Revenue by industry tells a clearer growth story than segments alone. Therapeutics revenue surged 39% YoY to $37.2M, directly reflecting the AI-discovery pull-through. This is now the largest industry vertical, overtaking diagnostics ($35.3M, flat YoY ex-customer). Global supply partners grew 50% YoY to $12.8M, driven by a significant new NGS partner coming online and APAC distributor growth. EMEA was the standout geography at 36% YoY growth to $38.4M, while Americas grew 9% and APAC was roughly flat.
Gross Margin Trajectory Validates Platform Economics
Gross margin of 52.0% extends the structural improvement: from 42.6% in FY24 to 50.7% in FY25, now above 52% for two consecutive quarters. The key metric management tracks—incremental revenue drop-through to gross profit—came in at 74% this quarter, within the 75-80% target range. This confirms the silicon-based platform's operating leverage: more products and volume flow through the same manufacturing infrastructure with minimal incremental cost. Management is deliberately moderating further margin expansion to fund growth, holding FY26 guidance at 'above 52%' rather than pushing for 54%+.
Gene Manufacturing Volume Scaling Rapidly
Twist shipped ~271,000 genes in Q1 FY26, up from ~205,000 in Q1 FY25—growth of 32%. Additionally, over 50,000 genes were manufactured internally for data characterization, a number disclosed for the first time because it has become material. This brings total gene manufacturing to 320,000+ in the quarter. The volume growth validates both the platform's scalability and the shift toward higher-value workflows where Twist delivers data rather than just DNA.
R&D Spending Declining While Innovation Accelerates
R&D expenses fell 20% YoY to $17.1M from $21.3M—continuing a multi-quarter decline from $24.1M in Q2 FY25. This reflects the maturation of the platform: new products are launched on top of existing manufacturing infrastructure with modest incremental investment. The proprietary polymerase development and NGS capacity expansion with fixed headcount (highlighted in Q2 FY25) exemplify this efficiency. The trade-off is visible in the SG&A ramp—spending is shifting from R&D to commercialization.
Cash Position Declining, Runway Requires EBITDA Improvement
Cash, cash equivalents, and short-term investments fell to $197.9M from $232.4M at FY25-end—a $34.5M decline in one quarter. Operating cash used was $24.8M, CapEx was $10.0M. At this quarterly burn rate (~$35M), the company has approximately 5-6 quarters of runway. If EBITDA breakeven is achieved in Q4 FY26 as guided, this is adequate. But if the timeline slips, the company may need to raise capital or cut spending. Notably, accrued compensation dropped from $31.3M to $18.8M—a $12.5M cash outflow from bonus payments that inflated this quarter's burn and should not fully repeat.
Competitive Positioning Strengthening
Management struck an unusually confident competitive tone. COO Finn stated they track competitors 'at a very intimate level' and are seeing early benchmarking data showing Twist is 'weeks faster than the competition.' They highlighted hiring salespeople while competitors are laying off. Customer count grew to 2,538 from 2,376 YoY (+7%). The serviceable addressable market has expanded from ~$2B in 2020 to ~$7B today, with a path to $12B+ by 2030. An investor day is planned for May 2026 to provide deeper product roadmap and market sizing.
Other KPIs
Stable YoY. Operating loss was -$32.9M vs -$34.6M a year ago—modest improvement despite the SG&A surge, because R&D declined by $4.2M and gross profit expanded by $11.0M. However, the sequential trend reversed: loss from operations worsened from -$29.9M in Q4 FY25. The SG&A increase entirely absorbed the gross profit gains.
AR decreased from $57.0M at FY25-end to $50.1M, suggesting healthy collections and no revenue quality concerns. DSO improved despite higher revenue. This is a positive signal given the revenue mix shift toward larger pharma and tech customers who typically have longer payment cycles.
Inventories rose 16% sequentially from $28.3M to $32.9M. This likely reflects deliberate build-up to support higher throughput demands from AI-discovery customers and the expected NGS re-acceleration in Q2. Worth monitoring—if revenue growth doesn't absorb this, it becomes a cash drag.
SBC rose 11% YoY from $12.0M, modest relative to headcount growth. SBC represents the primary adjustment between GAAP net loss (-$30.5M) and Adjusted EBITDA (-$13.4M), along with $6.2M in D&A. No unusual equity-related charges.
Guidance
Accelerating confidence. The midpoint of $437.5M implies ~16% YoY growth, consistent with the recent pace but higher than the prior midpoint of $430M. The $7.5M raise is roughly 2x the Q1 beat vs prior guidance, suggesting management sees strengthening trends beyond just one good quarter. The raise was described as 'generally balanced' across DSPS and NGS.
Stable. Implies ~16% YoY growth at the midpoint and ~3.7% sequential growth. Management specifically expects 'strong sequential growth' in NGS in Q2, driven by the return of the transitioning customer whose orders are now confirmed. DSPS growth should remain robust given AI-discovery pipeline visibility.
Stable, deliberately moderated. Despite achieving 52.0% in Q1, management held the FY guide at 'above 52%' rather than raising it. This reflects a trade-off: investing in additional operators, automation, and new characterization capabilities to support higher throughput. CFO Laponis was explicit: they'd rather build a multi-billion-dollar business at 50%+ margins than a $500M business at 60%. Expects continued improvement through the year at a 'moderated clip.'
Reiterated with higher execution risk. This target was set when EBITDA was on a clear improving trend (-$16.3M → -$7.8M over four quarters). The Q1 reversal to -$13.4M means the company now needs ~$13-14M of improvement over three quarters. Management says investments will 'remain stable or moderate slightly' in H2, so the path depends on revenue acceleration dropping through to gross profit while OpEx plateaus. CEO called breakeven 'a given for us now,' but the math is tighter than before.
Accelerating. FY26 guidance midpoint ($437.5M) minus Q1 ($103.7M) and Q2 midpoint ($107.5M) leaves $226.3M for Q3+Q4, averaging ~$113M per quarter. This implies meaningful sequential acceleration from Q2's ~$107.5M and would represent ~18% YoY growth if prior-year Q3+Q4 averaged ~$97.5M. Aggressive but consistent with management's commentary about commercial hiring payoff and NGS re-acceleration.
Key Questions
EBITDA Bridge to Breakeven
Adjusted EBITDA went from -$7.8M to -$13.4M sequentially. What is the specific quarterly bridge from here to Q4 breakeven? Will OpEx be flat, down, or still growing in Q3/Q4? How much of the ~$10M/quarter OpEx increase is truly transient versus structural?
AI Discovery Order Durability and Concentration
How many distinct AI-discovery customers generated material revenue in Q1? What is the reorder rate so far? Is there a concentration risk if one or two large pharma or tech accounts drive the majority of the DSPS acceleration?
NGS Re-acceleration Evidence
You stated the transitioning customer's orders are 'in.' What does Q2 NGS growth look like with this customer included? Is the path back to 20% YoY NGS growth by Q4 FY26 still realistic given diagnostics was flat this quarter?
Cash Sufficiency Without Raising Capital
With $198M in cash and ~$35M quarterly burn, do you have sufficient runway to reach self-sustaining cash flow without a capital raise? Is there a cash balance floor below which you would reconsider the investment pace?
MRD Xpress Launch Status
The MRD Xpress product was announced at Q4 FY25 with expected launch in early calendar 2026. What is the current status? Is the 1-2 points of FY26 growth contribution assumption still intact? No mention was made on today's call.